<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588844</url>
  </required_header>
  <id_info>
    <org_study_id>PEG-rhGH</org_study_id>
    <nct_id>NCT04588844</nct_id>
  </id_info>
  <brief_title>Effect of Growth Hormone Injection on the IVF/ICSI Outcome of Patients With Poor Ovarian Reserve.</brief_title>
  <official_title>Effect of Polyethylene Glycol Recombinant Human Growth Hormone Injection on the IVF/ICSI Outcome of Patients With Poor Ovarian Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Declined fertility and ovarian reserve in older women are associated with lower density of&#xD;
      Growth hormone (GH) receptors and dysregulation in GH secretion. GH can regulate the&#xD;
      expression of growth hormone receptor and strengthen the function of mitochondria, which&#xD;
      could improve the quality of the female oocyte. In this study, a prospective randomized&#xD;
      control will be conducted to explore the effect of GH adjuvant therapy on clinical outcome of&#xD;
      in vitro fertilization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be randomly assigned into either the study groups (receive somatropin&#xD;
      co-treatment) or the control group (without sopmatropin treatment). Polyethylene glycol&#xD;
      recombinant human somatropin will be injected weekly (3mg/per week) for approximately 6&#xD;
      weeks, i.e. from the beginning of preceding menstruation cycle until the day of ovum pickup.&#xD;
      Both groups will receive a similar common protocol for ovarian stimulation. In vitro&#xD;
      fertilization with or without intracytoplasmic sperm injection will be performed according to&#xD;
      semen parameters. All embryos will undergo culture for blastocyst and the obtained&#xD;
      blastocysts will be vitrified for deferred frozen embryo transfer. The Blastocyst formation&#xD;
      rate will be the primary outcome measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">March 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blastocyst formation rate</measure>
    <time_frame>One year</time_frame>
    <description>the number of blastocyst/ the total number of embryos underwent blastocyst culture ×100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of retrieved oocytes</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of high-score embryos</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total amount of Gn used</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total days of Gn administration</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E2 levels on triggering day</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness on triggering day</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Poor Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>Growth Hormone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth Hormone pretreatment for 6 weeks before ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No pretreatment before ovarian stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol Recombinant Human Somatropin</intervention_name>
    <description>Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.</description>
    <arm_group_label>Growth Hormone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1)Married women between 35-40 years old; 2) serum AMH&lt; 1.2ng/ml, and basal FSH&lt;20IU/L&#xD;
             during the screening period or within 6 months; 3) 18kg/m2≤BMI&lt;30kg/m2; 4) Previous&#xD;
             ART cycles &lt;3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1）Gynecological diseases that affect pregnancy outcomes, such as submucous uterine&#xD;
             myoma, intramural uterine myoma≥4cm, Ovarian cyst≥4cm, endometriosis, Uterine&#xD;
             malformation, Tuberculosis of reproductive system; 2) Spontaneous abortion≥3 times; 3)&#xD;
             Chromosomal abnormalities (except polymorphism) in one or both spouses; 4) Patients&#xD;
             with well-defined and uncontrolled endocrine, metabolic, and adrenal diseases, such as&#xD;
             diabetes, thyroid disease, Cushing's syndrome; 5) Patients with malignant tumors; 6)&#xD;
             Previous use of somatropin products.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daimin Wei</last_name>
    <phone>0531-85652419</phone>
    <email>sdweidaimin@163.com</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Chen Zi-Jiang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol and statistical analysis plan will be available online with publication. Data collected for the study, including specified data set and a data dictionary defining each field in the set, will be made available to others with publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After publication and for 1 year</ipd_time_frame>
    <ipd_access_criteria>Investigators can request data sharing by contacting the email of the corresponding author. Our publication committee established for this trial will review and approve the request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

